CpG oligodeoxynucleotide enhances tumor response to radiation

Cancer Research

Volumn 64, Issue 15, 2004, Pages 5074-5077

  Milas, Luka ^a   Mason, Kathryn A ^a   Ariga, Hisanori ^a   Hunter, Nancy ^a   Neal, Robert ^a   Valdecanas, David ^a   Krieg, Arthur M ^b   Whisnant, John K ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOSINE; GUANINE; OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER; CANCER RADIOTHERAPY; CELL DENSITY; CONTROLLED STUDY; CPG ISLAND; DENDRITIC CELL; DNA SEQUENCE; GRANULOCYTE; GROWTH INHIBITION; IMMUNE DEFICIENCY; INFLAMMATORY CELL; LYMPHOCYTIC INFILTRATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; WHOLE BODY RADIATION;

ANIMALS; LYMPHOCYTES, TUMOR-INFILTRATING; METHYLCHOLANTHRENE; MICE; MICE, INBRED C3H; NECROSIS; OLIGODEOXYRIBONUCLEOTIDES; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES; WHOLE-BODY IRRADIATION;

EID: 3442879246     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0926     Document Type: Article

References (20)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
2. Milas L, Scott MT. Antitumor activity of Corynebacterium parvum. Adv Cancer Res 1978;26:257-306.
3. Mihich E, Fefer A, editors. Biological Response Modifiers: Subcommittee Report. Monograph No. 63. Washington, DC: National Cancer Institute; 1983.
4. Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999;52:1-11.
5. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-9.
6. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740.
7. Uhlmann E, Vollmer J. Recent advances in the development of immunostimulatory oligodeoxynudeotides. Curr Opin Drug Discov Devel 2003;6:204-7.
8. Wild J, Grusby MJ, Schirmbeck R, Reimann J. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. J Immunol 1999;163:1880-7.
9. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997;27:2340-4.
10. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynudeotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997;186:1623-31.
11. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynudeotides. Clin Cancer Res 2003;9:2693-700.
12. Heckelsmiller K, Rall K, Beck S, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002;169:3892-9.
13. Blazar BR, Krieg AM, Taylor PA. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 2001;98:1217-25.
14. Krieg AM. Antitumor applications of stimulating Toll-like receptor 9 with CpG oligodeoxynudeotides. Curr Oncol Rep 2004;6:88-95.
15. Stone HB, Milas L. Modification of radiation response of murine tumors by misonidazole (Ro 07-0582), host immune capability, and Corynebacterium parvum. J Natl Cancer Inst 1978;6:887-93.
16. Milross CG, Tucker SL, Mason KA, Hunter NR, Peters LJ, Milas L. The effect of tumor size on necrosis and polarographically measured pO2. Acta Oncol 1997;36:183-9.
17. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-14.
18. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000;165:1228-35.
19. Suit HD, Sedlacek R, Wagner M, Orsil L, Silobrcic V, Rothman J. Effect of Corynebacterium parvum on the response to irradiation of a C3H fibrosarcoma. Cancer Res 1976;36:1305-14.
20. Krieg A, Efle S, Price J, Al-Adhami M, Whisnant J. Biomarker profile and clinical safety of S.C. or I.V. doses of Promune (CpG 7909 injection) a novel TLR-9 agonist oligodeoxynucleotide. J Immunother 2003;26:334.